Google's REPLIQA program is supporting academic researchers by funding projects that apply quantum science and artificial intelligence to the life sciences. This initiative aims to accelerate scientific discoveries and push the boundaries of understanding in fields essential to health and biology.

Novo Nordisk is taking an equity stake in Cellular Intelligence and stands to receive future milestone payments and royalties. Cellular Intelligence intends to apply its AI technology to STEM-PD, a stem-cell-derived Parkinson’s treatment that Novo discontinued in October last year. The transfer marks a strategic move to advance the therapy using AI innovation in biotech.

Within the gene therapy community, frustration mounts as Capsida has yet to disclose which brain receptor was involved when the adverse event occurred, delaying progress in understanding the incident.

Bristol Myers Squibb has entered into a significant agreement valued at up to $15.2 billion with Jiangsu Hengrui Medicine, the top pharmaceutical firm in China by market value. This partnership includes 13 early-stage drug programs spanning oncology, hematology, and immunology, none of which have yet commenced human clinical trials. The announcement coincided with Bristol Myers Squibb facing critical patent expirations, prompting the strategic collaboration.

The way patients interact with healthcare services is shifting dramatically as AI voice technologies redefine patient support. In 2026, clinics and hospitals are no longer limited by traditional office hours — patient inquiries happen anytime, anywhere, through AI-powered phone and chat systems providing seamless support around the clock. This evolution dramatically reduces missed calls, shortens wait times, and lightens administrative workloads by handling routine tasks such as appointment scheduling, patient registration, insurance verification, and basic triage efficiently and attentively. Beyond inbound interactions, AI voice agents proactively engage patients with follow-ups, reminders, and chronic care check-ins, offering a new level of personalized, continuous care. These advancements pave the way for greater operational efficiency, improved patient satisfaction, and enhanced clinical outcomes, bridging the gap between high-quality medical care and exceptional patient experience.

Operational efficiency ensures financial success and customer satisfaction by optimizing resources and minimizing delays. However, highly efficient systems often lack resilience, making organizations vulnerable to disruptions. This tension is evident in industries like airlines, where tight schedules maximize asset use but increase the risk of delays that cascade through networks, frustrating passengers and harming reputations. Beyond airlines, supply chains, healthcare, and call centers face similar challenges balancing cost, throughput, and customer experience.

Our research reveals that efficiency and resilience are not mutually exclusive. Three strategies help organizations achieve both:

1. Measure What Matters to Customers: Instead of relying on traditional metrics that don’t capture true service quality—like airlines' on-time performance (OTP), which can be misleading—organizations should adopt customer-centric metrics. For example, tracking passengers’ actual travel times, including delays and missed connections, better reflects customer experience and incentivizes resilience alongside speed.

2. Avoid One-Size-Fits-All Buffers: Strategic use of buffers, tailored to risk levels and disruption impact, can prevent minor delays from escalating. Airlines, hospitals, call centers, and supply chains can all improve resilience and efficiency by allocating resources dynamically based on data and disruption likelihood.

3. Curate Customer Options: Offering too many choices increases complexity and risk. By narrowing options to avoid risky itineraries or scheduling slots, organizations can reduce delays and disruptions without significantly compromising efficiency or customer satisfaction.

Implementing these strategies requires data-driven insights, cross-functional collaboration, and balancing short-term efficiency with long-term reliability. Companies that design operations for both resilience and efficiency rather than reacting post-disruption will better meet rising customer expectations and thrive in competitive markets.

Alphabet’s Isomorphic Labs has successfully raised $2.1 billion in a Series B funding round. The substantial investment will be dedicated to accelerating the deployment of its advanced AI model on a larger scale, enhancing its impact in drug discovery and related fields.

Copenhagen-based clinical AI firm Corti has introduced a no-equity accelerator program for healthcare and life sciences startups. The company is granting access to its Symphony AI model stack, which has outperformed OpenAI on the HealthBench Professional benchmark. Alongside free credits, Corti is providing regulatory guidance to support global founders navigating the increasingly stringent European regulatory landscape.

Steve D. Klein emphasizes that while AI has the potential to advance medical decision-making, direct and unregulated exchanges between AI systems and patients, particularly in addiction treatment, carry significant risks.

Takeda, a global pharmaceutical company with over 1,000 employees across four locations in Ireland, has announced plans to cut 4,500 jobs worldwide as part of a restructuring effort. This move aims to streamline operations amid changing market conditions.